11/24
07:00 am
dnth
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
11/10
08:03 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
11/7
07:07 pm
dnth
Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]
11/6
08:40 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.
Medium
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.
11/5
04:01 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Medium
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
11/4
08:00 am
dnth
Dianthus Therapeutics to Participate in Four Investor Conferences During November
Low
Report
Dianthus Therapeutics to Participate in Four Investor Conferences During November
10/29
03:30 pm
dnth
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Low
Report
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
10/16
11:40 pm
dnth
Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion [Yahoo! Finance]
Low
Report
Evaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline Expansion [Yahoo! Finance]
10/16
07:00 am
dnth
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
Low
Report
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
10/14
09:12 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $56.00 price target on the stock.
Medium
Report
Dianthus Therapeutics (NASDAQ:DNTH) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $56.00 price target on the stock.
10/2
08:05 am
dnth
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting [Yahoo! Finance]
Medium
Report
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting [Yahoo! Finance]
10/2
08:00 am
dnth
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Medium
Report
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
9/30
12:02 pm
dnth
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target [Yahoo! Finance]
Low
Report
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target [Yahoo! Finance]
9/14
03:55 am
dnth
Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise [Yahoo! Finance]
Medium
Report
Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise [Yahoo! Finance]
9/12
10:39 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Stifel Nicolaus from $52.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Stifel Nicolaus from $52.00 to $65.00. They now have a "buy" rating on the stock.
9/12
08:23 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $42.00 to $44.00. They now have an "outperform" rating on the stock.
Low
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $42.00 to $44.00. They now have an "outperform" rating on the stock.
9/11
04:07 pm
dnth
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/10
06:54 pm
dnth
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential [Yahoo! Finance]
Medium
Report
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential [Yahoo! Finance]
9/10
02:10 am
dnth
Dianthus Therapeutics Stock Earns RS Rating Upgrade [Yahoo! Finance]
Medium
Report
Dianthus Therapeutics Stock Earns RS Rating Upgrade [Yahoo! Finance]
9/9
10:42 pm
dnth
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering [Yahoo! Finance]
Medium
Report
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering [Yahoo! Finance]
9/9
10:35 pm
dnth
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
Medium
Report
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
9/9
11:21 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $63.00 price target on the stock, up previously from $56.00.
Medium
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $63.00 price target on the stock, up previously from $56.00.
9/9
09:06 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Guggenheim from $92.00 to $100.00. They now have a "buy" rating on the stock.
High
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Guggenheim from $92.00 to $100.00. They now have a "buy" rating on the stock.
9/9
08:07 am
dnth
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Robert W. Baird from $50.00 to $67.00. They now have an "outperform" rating on the stock.
High
Report
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Robert W. Baird from $50.00 to $67.00. They now have an "outperform" rating on the stock.
9/8
04:22 pm
dnth
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering [Yahoo! Finance]
High
Report
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering [Yahoo! Finance]